Commercialization, • 9/19/25 Designing Trials with the End in Mind: Building Market Access into Rare Disease Clinical Development Previous Purpose-Driven Metrics: Running Gene Therapy Trials with KPIs That Matter Next What Matters to Payers: Conversations You Should Start During Phase 2 You Might Also Like Operationalizing Precision Medicine in Rare Disease Trials Optimizing Rare Disease Clinical Trials with Real World Data Using NLP & AI Beyond Biotech: The Rise of Nontraditional Sponsors in Rare Disease Trials Patient Recruitment and Engagement in in Global, Multisite Rare Disease Trials Real-World Evidence That Matters: A Hands-On Workshop in Building Credible Value Stories
Commercialization, • 9/19/25 Designing Trials with the End in Mind: Building Market Access into Rare Disease Clinical Development Previous Purpose-Driven Metrics: Running Gene Therapy Trials with KPIs That Matter Next What Matters to Payers: Conversations You Should Start During Phase 2 You Might Also Like Operationalizing Precision Medicine in Rare Disease Trials Optimizing Rare Disease Clinical Trials with Real World Data Using NLP & AI Beyond Biotech: The Rise of Nontraditional Sponsors in Rare Disease Trials Patient Recruitment and Engagement in in Global, Multisite Rare Disease Trials Real-World Evidence That Matters: A Hands-On Workshop in Building Credible Value Stories
